Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy

Journal of Clinical Investigation

Volumn 122, Issue 7, 2012, Pages 2672-2679

  Zhao, Min ^a,b   Célérier, Isabelle ^a,c   Bousquet, Elodie ^a,b   Jeanny, Jean Claude ^a,b   Jonet, Laurent ^a,b   Savoldelli, Michèle ^d   Offret, Olivier ^b,d   Curan, Antoine ^b,d   Farman, Nicolette ^a,c   Jaisser, Frédéric ^a,c   Behar Cohen, Francine ^a,b,d  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CORTICOSTERONE; EPLERENONE; GLUCOCORTICOID; POTASSIUM CHANNEL;

ADULT; ARTICLE; CASE REPORT; CENTRAL SEROUS RETINOPATHY; CHOROID VASCULARIZATION; CHRONIC DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; EYE DISEASE; FEMALE; HUMAN; LEWIS RAT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECURRENT DISEASE; RETINA DETACHMENT; SIGNAL TRANSDUCTION; TREATMENT DURATION; VISUAL ACUITY;

ADULT; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; CENTRAL SEROUS CHORIORETINOPATHY; CHOROID; CORTICOSTERONE; HUMANS; MALE; MIDDLE AGED; RATS; RECEPTORS, MINERALOCORTICOID; RETINA; SIGNAL TRANSDUCTION; SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; SPIRONOLACTONE; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS; VISUAL ACUITY;

EID: 84863548606     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61427     Document Type: Article

References (35)

1. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol. 2001;280(2):F181-F192.
2. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology. Nucl Recept Signal. 2007;5:e012.
3. Nguyen Dinh Cat A, et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010;24(7):2454- 2463.
4. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol. 2012;350(2):256-265.
5. Zhao M, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Muller glial cells. FASEB J. 2010;24(9):3405-3415.
6. Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond). 2010;24(12):1743-1756.
7. Bae SH, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011;152(5):784-792.e2.
8. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47(5):431-448. (Pubitemid 35341618)
9. Pryds A, Sander B, Larsen M. Characterization of subretinal fluid leakage in central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2010;51(11):5853-5857.
10. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29(10):1469-1473.
11. Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina. 2011;31(8):1603-1608.
12. Carvalho-Recchia CA, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109(10):1834-1837.
13. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004;111(2):244-249. (Pubitemid 38183222)
14. Burnham MP, et al. Characterization of an apamin-sensitive small-conductance Ca(2+)-activated K(+) channel in porcine coronary artery endothelium: relevance to EDHF. Br J Pharmacol. 2002;135(5):1133-1143. (Pubitemid 34259113)
15. Brahler S, et al. Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation. 2009;119(17):2323-2332.
16. Escoubet B, Coureau C, Bonvalet JP, Farman N. Noncoordinate regulation of epithelial Na channel and Na pump subunit mRNAs in kidney and colon by aldosterone. Am J Physiol. 1997;272(5 pt 1):C1482-C1491.
17. Wald H, Garty H, Palmer LG, Popovtzer MM. Differential regulation of ROMK expression in kidney cortex and medulla by aldosterone and potassium. Am J Physiol. 1998;275(2 pt 2):F239-F245.
18. Benitah JP, Perrier E, Gomez AM, Vassort G. Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes. J Physiol. 2001;537(pt 1):151-160. (Pubitemid 33076962)
19. Weatherall KL, Seutin V, Liegeois JF, Marrion NV. Crucial role of a shared extracellular loop in apamin sensitivity and maintenance of pore shape of small-conductance calcium-activated potassium (SK) channels. Proc Natl Acad Sci U S A. 2011;108(45):18494-18499.
20. Struthers AD. Aldosterone-induced vasculopathy. Mol Cell Endocrinol. 2004;217(1-2):239-241. (Pubitemid 38596648)
21. Funder JW. Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis. 2010;52(5):393-400.
22. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51(2):161-167. (Pubitemid 351159920)
23. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47(3):312-318. (Pubitemid 43740260)
24. Griol-Charhbili V, Fassot C, Messaoudi S, Perret C, Agrapart V, Jaisser F. Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension. 2011;57(2):238-244.
25. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350(2):266-272.
26. Leopold JA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13(2):189-197.
27. Heylen E, Huang A, Sun D, Kaley G. Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone. J Cardiovasc Pharmacol. 2009;54(6):535-542.
28. Bafford R, et al. Mineralocorticoid receptor expression in human venous smooth muscle cells: a potential role for aldosterone signaling in vein graft arterialization. Am J Physiol Heart Circ Physiol. 2011;301(1):H41-H47.
29. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res. 2009;104(1):124-133.
30. Frindt G, Ergonul Z, Palmer LG. Surface expression of epithelial Na channel protein in rat kidney. J Gen Physiol. 2008;131(6):617-627. (Pubitemid 351749201)
31. Soundararajan R, Pearce D, Hughey RP, Kleyman TR. Role of epithelial sodium channels and their regulators in hypertension. J Biol Chem. 2010;285(40):30363-30369.
32. Edwards G, Feletou M, Weston AH. Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch. 2010;459(6):863-879.
33. White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev. 1997;18(1):135-156. (Pubitemid 27076458)
34. Fischer MD, et al. Noninvasive, in vivo assessment of mouse retinal structure using optical coherence tomography. PLoS One. 2009;4(10):e7507.
35. Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146(4):496-500.